Motley Fool Australia
  •  
  • Log Out
  • Menu
  1. Stocks
    2. /
  2. Clarity Pharmaceuticals Ltd (ASX: CU6)
    3. /

Clarity Pharmaceuticals Ltd (ASX: CU6) Share Price and News

Price

$2.23

Movement

0.16 (-6.7%)

as at 11 Jun 1:03pm (20 mins delayed)

52 Week Range

$1.43 - $8.975

 
1 Year Return

-57.03%

Clarity Pharmaceuticals Ltd Chart and Price Data

2025
2025
2025
2025
$0
$5
$10
$0
$5
$10
$0
$5
$10
$0
$5
$10

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $768.03 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 321.35 million
Earnings per share -0.163
Dividend per share N/A
Year To Date Return -46.04%
Earnings Yield N/A
Franking -
Earnings Yield

N/A

Franking

-

Dividend per share

N/A

Year To Date Return

-46.04%

Shares Outstanding

321.35 million

Earnings per share

-0.163

Share Price

$2.23

Day Change

0.16 (-6.7%)

52 Week Range

$1.43 - $8.975

Yesterday's Close

$2.39

Today's Open

$2.43

Days Range

$2.17 - $2.43

Volume

2,230,425

Avg. Volume (1 month)

2,949,883

Turnover

$5,004,673

as at 11 Jun 1:03pm

    • Clarity Pharmaceuticals Ltd (ASX: CU6)
    Latest News

    Elderly couple look sideways at each other in mild disagreement
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a disappointing end to the trading week for ASX investors this Friday...

    Read more »

    Two lab workers fist pump each other.
    Healthcare Shares

    2 buy-rated ASX 200 healthcare shares to bring your portfolio to life in 2025

    | James Mickleboro

    Bell Potter is expecting healthy returns from these stocks this year.

    Read more »

    A group of people at a party look upwards to the camera as they celebrate the rise of ASX value shares
    Share Gainers

    16 ASX shares that doubled in value last year

    | Bronwyn Allen

    There were multiple ASX All Ords stocks that delivered double-or-more share price growth in 2024.

    Read more »

    A businessman compares the growth trajectory of property versus shares.
    Share Market News

    Shares vs. property: Which investment delivered the best capital growth in 2024?

    | Bronwyn Allen

    Where did home values rise by almost 20%? And which ASX 200 stock more than tripled in value?

    Read more »

    Ten happy friends leaping in the air outdoors.
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    Investors enjoyed a pleasant ASX session this Tuesday...

    Read more »

    Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
    Healthcare Shares

    Healthy gains: 5 best ASX 200 healthcare shares of 2024

    | Bronwyn Allen

    Four of the five best-performing ASX 200 healthcare stocks of 2024 more than doubled in value.

    Read more »

    Excited group of friends sitting on sofa watching sports on TV and celebrating.
    Share Gainers

    Why Clarity, Omni Bridgeway, Santana Minerals, and Vulcan shares are pushing higher today

    | James Mickleboro

    These shares are having a good time on hump day. But why?

    Read more »

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Healthcare Shares

    Guess which ASX healthcare stock is jumping 12% on Wednesday

    | James Mickleboro

    This shares is rocketing this morning. But why? Let's find out.

    Read more »

    a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
    Healthcare Shares

    The best ASX 200 healthcare stocks to buy in 2025

    | James Mickleboro

    These shares could give your portfolio a healthy boost next year according to Bell Potter.

    Read more »

    Ten smiling business people wave to the camera after receiving some winning company news.
    ETFs

    Vanguard Australian Shares Index ETF has lifted 20% in a year. Which stocks have contributed most to its rise?

    | Bronwyn Allen

    This popular ASX ETF seeks to track the performance of the S&P/ASX 300 Index before fees.

    Read more »

    Three shareholders climbing ladders up into the clouds
    Share Gainers

    11 ASX All Ords shares rising faster than Nvidia over the past year

    | Bronwyn Allen

    Who knew? Here are the homegrown ASX companies outperforming Nvidia on share price growth over the past 12 months.

    Read more »

    Three women cruise along enjoying ice-creams in the sunshine.
    Best Shares

    3 ASX 300 stocks up by more than 300% in a year

    | Bronwyn Allen

    These stocks certainly add up to a triple treat.

    Read more »

    CU6 ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    5th Jun 2025 2025-06-05T09:49:22 DISCO topline resultsYesNo9:49am6382k
    5th Jun 2025 2025-06-05T08:22:46 Ceasing to be a substantial holderYesNo8:22am3256k
    30th May 2025 2025-05-30T11:08:13 Notification regarding unquoted securities - CU6YesNo11:08am616k
    29th May 2025 2025-05-29T09:34:00 First patient imaged in Phase III AMPLIFY trialYesNo9:34am4336k
    20th May 2025 2025-05-20T09:55:45 AMPLIFY trial commencesYesNo9:55am4341k
    15th May 2025 2025-05-15T16:24:02 Ceasing to be a substantial holderYesNo4:24pm5452k
    13th May 2025 2025-05-13T15:43:51 Becoming a substantial holderYesNo3:43pm27393k
    2nd May 2025 2025-05-02T08:26:11 Change in substantial holdingYesNo8:26am261.5M
    30th Apr 2025 2025-04-30T15:06:09 Quarterly Activities/Appendix 4C Cash Flow ReportYesNo3:06pm338.8M
    22nd Apr 2025 2025-04-22T18:51:37 Change in substantial holdingYesNo6:51pm271.4M

    About Clarity Pharmaceuticals Ltd

    Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products. The company was founded by Matthew Harris on April 8, 2010 and is headquartered in Eveleigh, Australia.

    CU6 Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    10 Jun 2025 $2.39 $0.14 6.22% 2,001,966 $2.30 $2.43 $2.27
    06 Jun 2025 $2.25 $-0.08 -3.43% 2,426,296 $2.32 $2.41 $2.23
    05 Jun 2025 $2.33 $0.25 12.02% 4,510,379 $2.24 $2.35 $2.11
    04 Jun 2025 $2.08 $0.08 4.00% 1,783,034 $2.03 $2.11 $2.02
    03 Jun 2025 $2.00 $0.11 5.80% 2,844,113 $1.91 $2.02 $1.86
    02 Jun 2025 $1.90 $-0.27 -12.50% 4,959,828 $2.12 $2.12 $1.84
    30 May 2025 $2.16 $0.00 0.00% 12,178,171 $2.15 $2.19 $2.09
    29 May 2025 $2.16 $0.01 0.47% 4,123,158 $2.20 $2.37 $2.12
    28 May 2025 $2.15 $-0.06 -2.71% 1,892,186 $2.28 $2.30 $2.09
    27 May 2025 $2.21 $0.00 0.00% 913,951 $2.24 $2.26 $2.16
    26 May 2025 $2.21 $0.01 0.45% 1,036,820 $2.20 $2.28 $2.16
    23 May 2025 $2.20 $-0.09 -3.93% 989,894 $2.26 $2.29 $2.19
    22 May 2025 $2.29 $-0.03 -1.29% 949,564 $2.27 $2.30 $2.22
    21 May 2025 $2.32 $0.03 1.31% 2,560,062 $2.32 $2.50 $2.31
    20 May 2025 $2.29 $0.11 5.05% 2,215,200 $2.22 $2.30 $2.19
    19 May 2025 $2.18 $-0.32 -12.80% 2,988,356 $2.40 $2.41 $2.17
    16 May 2025 $2.50 $-0.02 -0.79% 1,405,623 $2.56 $2.58 $2.46
    15 May 2025 $2.52 $0.03 1.20% 1,723,734 $2.49 $2.58 $2.40
    14 May 2025 $2.49 $-0.07 -2.73% 2,286,003 $2.60 $2.60 $2.43
    13 May 2025 $2.56 $0.34 15.32% 5,313,209 $2.28 $2.68 $2.28

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    20 Nov 2024 Christopher Roberts Issued 17,080 $93,018
    Issue of options. Indicative value, BlackScholes valuation using the 5-day VWAP
    20 Nov 2024 Rosanne Robinson Issued 17,080 $93,018
    Issue of options. Indicative value of $93,018 using a BlackScholes valuation using the 5-day VWAP
    20 Nov 2024 Alan Taylor Issued 740,748 $2,041,200
    Issue of options. Black-Scholes
    valuation, Monte Carlo
    simulation , Indicative value, VWAP
    20 Nov 2024 Colin Biggin Issued 285,918 $787,875
    Issue of options. Black-Scholes
    valuation, Monte Carlo
    simulation , Indicative value, VWAP
    20 Nov 2024 Thomas Ramdahl Issued 17,080 $93,018
    Issue of options. Indicative value of $93,018 using a BlackScholes valuation using the 5-day VWAP
    20 Nov 2024 Michelle Parker Issued 172,356 $613,750
    Issue of options. Black-Scholes valuation, Monte Carlo simulation, vwap, Indicative value
    02 Oct 2024 Michelle Parker Buy 542,710 $495,000
    Exercise of options. vwap
    02 Oct 2024 Michelle Parker Exercise 600,000 $495,000
    Exercise of options. vwap
    01 Oct 2024 Thomas Ramdahl Buy 200,000 $165,000
    Exercise of options. vwap
    01 Oct 2024 Thomas Ramdahl Exercise 200,000 $165,000
    Exercise of options. vwap
    01 Oct 2024 Colin Biggin Exercise 1,200,000 $990,000
    Exercise of options. VWAP
    01 Oct 2024 Colin Biggin Buy 1,084,321 $990,000
    Exercise of options. VWAP
    01 Oct 2024 Alan Taylor Exercise 1,200,000 $990,000
    Exercise of options. VWAP
    01 Oct 2024 Alan Taylor Buy 1,083,776 $990,000
    Exercise of options. VWAP
    01 Oct 2024 Christopher Roberts Exercise 200,000 $165,000
    Exercise of options. VWAP
    01 Oct 2024 Christopher Roberts Buy 200,000 $165,000
    Exercise of options. VWAP
    17 Sep 2024 Rosanne Robinson Exercise 200,000 $165,000
    Exercise of options.
    17 Sep 2024 Rosanne Robinson Buy 178,079 $165,000
    Exercise of options.
    07 Aug 2024 Colin Biggin Buy 905,625 $605,000
    Exercise of options. vwap
    07 Aug 2024 Colin Biggin Exercise 1,000,000 $605,000
    Exercise of options. vwap
    01 Aug 2024 Colin Biggin Exercise 600,000 $363,000
    Exercise of options. VWAP
    01 Aug 2024 Colin Biggin Buy 542,835 $363,000
    Exercise of options. VWAP
    01 Aug 2024 Alan Taylor Buy 543,002 $363,000
    Exercise of options.
    01 Aug 2024 Alan Taylor Exercise 600,000 $363,000
    Exercise of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Christopher Graham Roberts Non-Executive Director Mar 2016
    Dr Roberts has over 40 years of experience in the medical innovation space and has served on the boards of a number of ASX-listed companies during his career. He is member of Risk Committee.
    Ms Rosanne Elizabeth Robinson Lead Independent DirectorNon-Executive Director Oct 2010
    Ms Robinson brings experience in the nuclear field and a range of commercial and operational expertise to the Group. She has over 25 years of experience in senior leadership and governance roles in public and private companies and government. She is member of Risk Committee.
    Dr Alan John Taylor Executive ChairmanExecutive Director Nov 2013
    Dr Taylor has over 15 years of investment banking experience focused predominantly on the life sciences sector, and has significant expertise in capital raisings, mergers and acquisitions, and general corporate advisory.
    Dr Colin David Biggin Chief Executive OfficerManaging Director Oct 2019
    Dr Biggin has over 15 years of radiopharmaceutical development and commercialisation experience. Dr Biggin previously served with Algeta ASA during the development and commercialisation of its product Xofigo for metastatic prostate cancer, which was approved by the US FDA in 2013. Prior to joining the Company, Dr Biggin also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals.
    Ms Michelle Parker Executive Director Sep 2024
    Ms Parker has over 20 years of experience spanning nuclear medicine, positron emission tomography and pharmaceuticals in Australia and internationally. Prior to joining Clarity, Ms Parker held the position of Head of International Clinical Research Operations at Novartis Australia
    Mr Robert Cochrane Vickery Chief Financial OfficerCompany Secretary
    -
    David Green Chief Financial Officer
    -
    Robert Cochrane Vickery Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited 22,818,280 7.23%
    UBS Nominees Pty Ltd 19,336,534 6.12%
    Cabbit Pty Ltd Atf Robwill Trust 17,911,280 5.67%
    J P Morgan Nominees Australia Pty Limited 16,935,337 5.36%
    T M Ventures Pty Ltd 16,699,842 5.29%
    HSBC Custody Nominees (Australia) Limited 14,248,257 4.51%
    A.C.N. 136 437 913 Pty Ltd Atf The Taylor Family A/C 13,266,660 4.20%
    Argo Investments Limited 9,802,322 3.10%
    Yarrawah Pty Ltd Atf Peter Henderson P/L S/F A/C 8,040,000 2.55%
    Vantres Pty Ltd Atf Asten Super Fund A/C 6,812,340 2.16%
    Boorris Pty Ltd Atf Boorris Trust 6,065,800 1.92%
    BNP Paribas Noms Pty Ltd 5,356,049 1.70%
    Pacific Custodians Pty Limited 5,280,485 1.67%
    Smarter Capital Pty Ltd 5,004,543 1.58%
    National Nominees Limited 4,438,511 1.41%
    Kylaco Pty Ltd 3,896,280 1.23%
    Bnp Paribas Nominees Pty Ltd 3,713,550 1.18%
    Australian Nuclear Science & Technology Organisation 3,599,920 1.14%
    Colin Biggin 3,249,764 1.03%
    Wyargine Holdings Pty Ltd Atf Shellcove Super Fund 3,210,425 1.02%

    Profile

    since

    Note